Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
5 hedge funds and large institutions have $64K invested in Dermata Therapeutics Warrant in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
14% less capital invested
Capital invested by funds: $74K → $64K (-$10K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$899 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$20 |
DRMAW Hedge Fund Activity: Q3 2022 in Review
5 of the 5,796 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q3 2022, worth a combined $64K — down 14% from $74K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new DRMAW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $899. The largest seller was Warberg Asset Management, cutting an estimated $20.
- 5 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q3 2022, up from 4 in Q2 2022.
- Funds reported $64K of Dermata Therapeutics Warrant stock for Q3 2022, down 14% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics Warrant positions in Q3 2022 and 0 closed out, a net change of +1 holder.
- The largest Dermata Therapeutics Warrant buyer in Q3 2022 was UBS Group, an estimated $899 added.
- The largest Dermata Therapeutics Warrant seller in Q3 2022 was Warberg Asset Management, an estimated $20 sold.
Based on aggregated 13F filings for Q3 2022.